ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1442

Role of Platelet-bound Complement Activation Product (PC4d) in Predicting Risk of Future Thrombotic Events in Systemic Lupus Erythematosus

Anca Askanase1, John Conklin2, Michelle Petri3, Vasileios Kyttaris4, Yevgeniya Gartshteyn5, Wei Tang1, Anja Kammesheidt6 and Roberta Alexander2, 1Columbia University Medical Center, New York, NY, 2Exagen, Inc., Vista, CA, 3Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 4Beth Israel Deaconess Medical Center, Boston, MA, 5Columbia University Medical Center, Glen Rock, NJ, 6self, Laguna Beach, CA

Meeting: ACR Convergence 2022

Keywords: Autoantibody(ies), Biomarkers, Cardiovascular, complement, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Platelet-bound complement activation products (PC4d) are associated with a history of thrombosis in systemic lupus erythematosus (SLE) (Gartshteyn al., 2021; Petri et al., 2017). The current study evaluated the role of PC4d in assessing the risk of future thrombosis.

Methods: PC4d (expressed at net mean fluorescence intensity [MFI]) was measured by flow cytometry from patients enrolled in the Lupus Cohorts at Columbia Univ (COL), Johns Hopkins Univ (JH) and Beth Israel Deaconess Medical Center (BI) between Apr-Sep 2017 (JH), Aug 2018-Jan 2020 (COL), and Oct 2018-Mar 2022 (BI). History of thrombotic vascular events was confirmed by medical record review. Data were analyzed by chi-square and logistic regression. Diagnostic odds ratio (DOR) was calculated. If a patient had 2 arterial or 2 venous events, only the closest in time to PC4d measurement was included in the analysis.

Results: A total of 419 SLE patients were enrolled. Main demographic and clinical characteristics are in Table 1. Seventy-four thrombotic events occurred in the 5 years pre- to 3 years post-PC4d measurement. Of these 74, 50% had PC4d≥10 MFI at enrollment while 72% of patients without thrombosis had PC4d< 10 (p< 0.001). 19 events occurred in 15 subjects in the 3 years after PC4d measurement: 8 cerebrovascular accidents, 3 deep vein thrombosis, 2 gastrointestinal infarctions, 2 myocardial infarctions, 1 pulmonary infarction, 1 arterial thrombosis and 2 venous thrombosis not specified. Median PC4d was higher in the 15 patients with than in the 404 patients without thrombosis (12.2 MFI, IQR: 4.7-19.6 vs. 4.9 MFI, IQR: 2.6-13.6, p=NS) (Figure 1). When the arterial events closest to PC4d measurements (8 of 14 total arterial events) were included, PC4d >13 MFI had sensitivity=62%, specificity=74%, DOR=4.8 (95%CI: 1.1, 20.3), p=0.034 in predicting future arterial thrombosis in patients with a previous arterial thrombosis. As expected, a previous arterial thrombosis was a strong predictor of a subsequent arterial event (p=0.0042). PC4d≥10 or ≥20 MFI did not reach statistical significance for future thrombosis neither in the entire population (p=0.055 and 0.51, respectively) nor in the subgroup younger than 65 years old (p = 0.99 for both). However, the negative predictive value of PC4d< 10 MFI was 98%, indicating that probability of not having a thrombosis within 3 years is 98% if PC4d< 10 MFI. Of the 285 patients with PC4d< 10 MFI, 105 (37%) were positive for at least 1 of 8 anti-phospholipid antibodies (aPL) (3 aCL, 3 anti-B2GP1, or 2 anti-PS/PT antibodies), and 22 (7.8%) were positive for 3 aPL, indicating that the probability of not having a thrombosis if PC4d< 10 MFI holds true for the population aPL positive and presumed at higher risk.

Conclusion: PC4d≥10 MFI is associated with thrombosis in SLE and predicts future arterial thrombosis (DOR=4.8), despite the small number of events post-PC4d. Interestingly, patients with PC4d < 10 MFI have a 98% probability of not experiencing a thrombotic event in the following 3 years. Taken together, these findings suggest that PC4d levels help evaluate the risk of thrombosis in SLE and can guide the decision to start low dose aspirin.

Supporting image 1

Table 1. Demographic characteristics of the patients in the 3 cohorts and overall.
Data is reported as number (n) and percentages (%). Anti-phospholipid (aPL) positivity was based on positivity for any of the isotypes: anti-phosphatidylserine/prothrombin complex (PS/PT) IgG or IgM, anti-cardiolipin (aCL) IgG, IgM, or IgA, and anti-beta2-glycoprotein1 (aB2GP1) IgG, IgM, or IgA.

Supporting image 2

Figure 1. Box and whisker plot with PC4d levels (net MFI) in patients who experienced (right) or not (left) thrombotic events post-PC4d measurement.


Disclosures: A. Askanase, AstraZeneca, GlaxoSmithKlein(GSK), Aurinia, Amgen, Pfizer, Idorsia, Eli Lilly, UCB, AbbVie/Abbott, Janssen, Bristol-Myers Squibb(BMS); J. Conklin, Exagen, Inc.; M. Petri, Exagen, AstraZeneca, Alexion, Amgen, AnaptysBio, Argenx, Aurinia, Biogen, Caribou Biosciences, CVS Health, EMD Serono, Eli Lilly, Emergent Biosolutions, GlaxoSmithKline (GSK), IQVIA, Janssen, Kira Pharmaceuticals, MedShr, Sanofi, SinoMab, Thermofisher, BPR Scientific Advisory Committee; V. Kyttaris, Exagen, Corbus Pharmaceuticals, Aurinia Pharmaceuticals, Scipher; Y. Gartshteyn, None; W. Tang, None; A. Kammesheidt, Exagen Inc.; R. Alexander, Exagen Inc..

To cite this abstract in AMA style:

Askanase A, Conklin J, Petri M, Kyttaris V, Gartshteyn Y, Tang W, Kammesheidt A, Alexander R. Role of Platelet-bound Complement Activation Product (PC4d) in Predicting Risk of Future Thrombotic Events in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/role-of-platelet-bound-complement-activation-product-pc4d-in-predicting-risk-of-future-thrombotic-events-in-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/role-of-platelet-bound-complement-activation-product-pc4d-in-predicting-risk-of-future-thrombotic-events-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology